Asset Details
Do you wish to reserve the book?
Development of Novel Pharmaceutical Agents for Alzheimer’s Disease: The Impact of Regulatory Initiatives in Japan and the United States
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Development of Novel Pharmaceutical Agents for Alzheimer’s Disease: The Impact of Regulatory Initiatives in Japan and the United States
Do you wish to request the book?
Development of Novel Pharmaceutical Agents for Alzheimer’s Disease: The Impact of Regulatory Initiatives in Japan and the United States
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Development of Novel Pharmaceutical Agents for Alzheimer’s Disease: The Impact of Regulatory Initiatives in Japan and the United States
2015
Overview
The incidence of Alzheimer’s disease (AD) has been steadily increasing worldwide. AD is a serious disease that has both societal and economic impacts. The greatest risk factor for AD is aging. Thus, because of the rapidly aging population in Japan, the development of new, effective drugs for AD is urgently needed. The goal of the present article was to analyze the status, clarify the problems, and discuss the scientific and political challenges of disease-modifying drug development for AD.
Public data, official documents, literature, and news releases were surveyed and discussed.
Compared with diabetes mellitus drugs, there is a lack of quantitative surrogate end points among AD drugs. Much AD drug development has focused on amyloid-β and its associated pathways; however, these drugs have not shown efficacy in Phase III clinical trials. Thus, the US Food and Drug Administration has appealed for a new draft industrial guidance for the development of AD drugs, including those for early-stage AD. In Japan, the Minister of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency have also taken action, including the publication of potential new guidelines for clinical evaluation and development of new AD therapeutics, including drugs. Moreover, scientific initiatives to develop novel AD drugs are ongoing.
The development of quantitative surrogate end points remains necessary to improve the development of AD drugs. Therefore, collaboration among industry, government, and academia should be encouraged. Following the principles of regulatory science, strategies to develop drugs for illnesses with unmet needs can be framed by investigating the effects of past, current, and future AD drug development initiatives.
Publisher
Elsevier Inc,Elsevier Limited
Subject
/ Age
/ Aging
/ Alzheimer Disease - drug therapy
/ Alzheimer’s disease (AD) drug development
/ Clinical Trials, Phase III as Topic
/ Dementia
/ Diabetes
/ Drug Approval - legislation & jurisprudence
/ Drugs
/ Humans
/ Japan
/ Neuroprotective Agents - therapeutic use
/ Pharmaceuticals and Medical Devices Agency
/ Studies
